Letters to the Editor
Vol. 13 No. 1 (2021): Mediterranean Journal of Hematology and Infectious Diseases, Volume 13, 2021
https://doi.org/10.4084/mjhid.2021.022

Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: November 28, 2020
Accepted: January 17, 2021
Published: February 26, 2021
1546
Views
452
Downloads
211
HTML
chronic myeloid leukemia, TKI, COVID-19

Authors

Judit Demeter
demeter.judit@med.semmelweis-univ.hu
Semmelweis University, Budapest, Hungary, Hungary.
Julia Weisinger
Semmelweis University, Budapest, Hungary, Hungary.
Zsolt Nagy
Semmelweis University, Budapest, Hungary, Hungary.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
] Merkely B, Szabó AJ, Kosztin A, Berényi E, Sebestyén A, Lengyel C, Merkely G, Karády J, Várkonyi I, Papp C, Miseta A, Betlehem J, Burián K, Csóka I, Vásárhelyi B, Ludwig E, Prinz G, Sinkó J, Hankó B, Varga P, Fülöp GÁ, Mag K, Vokó Z; HUNgarian COronaVirus-19 Epidemiological Research (H-UNCOVER) investigators. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. Geroscience. 2020 ; 42(4):1063-1074.
https://doi.org/10.1007/s11357-020-00226-9.
. Kemenesi G, Kornya L, Tóth GE, Kurucz K, Zeghbib S, Somogyi BA, Zöldi V, Urbán P, Herczeg R, Jakab F. Nursing homes and the elderly regarding the COVID-19 pandemic: situation report from Hungary. Geroscience. 2020 ; 1–7. https://doi.org/10.1007/s11357-020-00195-z.
.Abruzzese E, Luciano L, D’Agostino F, Trawinska M, Pane F, De Fabritiis P. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in infection. Mediterr J Hematol Infect Dis 2020 ;12(1): e2020031, DOI: http://dx.doi.org/10.4084/MJHID.2020.031
.Breccia M, Girmenia C, Latagliata R, Loglisci G, Santopietro M, Federico V, Petrucci L, Serrao A, Salaroli A, Alimena G. Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. Mediterr J Hematol Infect Dis. 2011 ;3(1):e2011021.
https://doi.org/10.4084/mjhid.2011.021
.Sorà F, Chiusolo P, Laurenti L, Innocenti I, Autore F, Alma E, Viscovo M, Fusco D, Maresca M, Tumbarello M, Sica S. SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation. Transfus Apher Sci. 2020 ; 102881.
https://doi.org/10.1016/j.transci.2020.102881.
. Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, You Y, Chen Z, Chen S, Wan C, Zhu X, Chang W, Sheng L, Cheng H, Zhang Y, Li Q, Qin J; Hubei Anti-Cancer Association, Meng L, Jiang Q. Leukemia. 2020 ;34(7):1799-1804. https://doi.org/10.1038/s41375-020-0853-6.
. Ba?c? S, Ata N, Altunta? F, Yi?eno?lu TN, Dal MS, Korkmaz S, Namdaro?lu S, Ba?türk A, Hac?bekiro?lu T, Do?u MH, Berber ?, Dal K, Erkurt MA, Turgut B, Ça?layan M, Ayval? MO, Çelik O, Ülgü MM, Birinci ?; Turkish Ministry of Health, Hematology Scientific Working Group. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2020; 26(7):1676-1682. https://doi.org/10.1177/1078155220953198
. Breccia M, Abruzzese E, Bocchia M, Bonifacio M, Castagnetti F, Fava C, Galimberti S, Gozzini A, Gugliotta G, Iurlo A, Latagliata R, Luciano L, Pregno P, Rege-Cambrin G, Rosti G, Stagno F, Tiribelli M, Foà R, Saglio G; Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Campus CML working group. Leukemia. 2020;34(8):2260-2261. https://doi.org/10.1038/s41375-020-0904-z.
Judit Demeter, Semmelweis University, Budapest, Hungary

Department of Internal Medicine and Oncology, Division of Hematology

MD, Full Professor 

ORCID ID: 0000-0001-8745-0757

Julia Weisinger, Semmelweis University, Budapest, Hungary

Department of Internal Medicine and Oncology, Division of Hematology

Zsolt Nagy, Semmelweis University, Budapest, Hungary

Department of Internal Medicine and Oncology, Division of Hematology

How to Cite



“Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption” (2021) Mediterranean Journal of Hematology and Infectious Diseases, 13(1), p. e2021022. doi:10.4084/mjhid.2021.022.
Copyright (c) 2021 Professor , MD, MD, Associate Professor Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.